Pancreatic Cancer Research

ResearcherMassachusetts General HospitalActive in the last 2 years

Junpei Yamaguchi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5892-5271; OpenAlex author ID A5060818759. Sources: OpenAlex.

Their work

Papers
20 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 3 papers · 2024: 2 papers · 2025: 3 papers · 2026: 4 papers

Papers 20

  1. Clinical Outcomes of Gemcitabine Plus Nab-Paclitaxel-Based Chemoradiotherapy in a Multidisciplinary Treatment Strategy for Locally Advanced Pancreatic Cancer (… Co-author DOI 10.1002/ijc.70801↗
  2. Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine With Nab-Paclitaxel) for Borderline-Resectable Pancreatic Cancer: Long-Term Results of a Randomized Control… Co-author DOI 10.1002/jhbp.70150↗
  3. High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-025-18912-3↗
  4. ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-026-19134-x↗
  5. Close correlation between patients' positive mood and postoperative complication burden in hepato-biliary-pancreatic cancer: a prospective comparative cohort t… Co-author DOI 10.1016/j.hpb.2025.07.015↗
  6. FUT2 and FUT3-specific normalization of DUPAN-2 and carbohydrate antigen 19-9 in preoperative therapy for pancreatic cancer: multicentre retrospective study (G… Co-author DOI 10.1093/bjs/znaf049↗
  7. FAM111B Suppression Enhances Sensitivity to Gemcitabine in Pancreatic Cancer Through Intracellular pH Regulation. Co-author DOI 10.1111/cas.70212↗
  8. Trefoil factor 1 suppresses stemness and enhances chemosensitivity of pancreatic cancer. Co-author DOI 10.1002/cam4.7395↗
  9. Impact of sarcopenia on biliary drainage during neoadjuvant therapy for pancreatic cancer. Co-author DOI 10.5946/ce.2022.278↗
  10. Impact of skeletal muscle mass on the prognosis of patients undergoing neoadjuvant chemotherapy for resectable or borderline resectable pancreatic cancer. First author DOI 10.1007/s10147-023-02321-1↗
  11. Antitumor Effects of Deep Ultraviolet Irradiation for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16198↗
  12. Cyclodextrin Conjugated α-Bisabolol Suppresses FAK Phosphorylation and Induces Apoptosis in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16245↗
  13. Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01). Co-author DOI 10.1097/sla.0000000000005430↗
  14. Tumor marker recovery rather than major pathological response is a preferable prognostic factor in patients with pancreatic ductal adenocarcinoma with preopera… Co-author DOI 10.1002/jhbp.748↗
  15. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 … Co-author DOI 10.18999/nagjms.81.2.233↗
  16. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. Co-author DOI 10.1007/s00280-018-3554-3↗
  17. Trefoil factor family 1 expression in the invasion front is a poor prognostic factor associated with lymph node metastasis in pancreatic cancer. First author DOI 10.1016/j.pan.2017.07.188↗
  18. The Anticancer Effects of Novel α-Bisabolol Derivatives Against Pancreatic Cancer. Co-author DOI 10.21873/anticanres.11352↗
  19. Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer. Co-author DOI 10.1002/cam4.453↗
  20. Sonic Hedgehog in pancreatic cancer: from bench to bedside, then back to the bench. Co-author DOI 10.1016/j.surg.2012.05.030↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yukihiro Yokoyama · 17 shared papers, 2015–2026 · strength 2.66
  2. Tomoki Ebata · 12 shared papers, 2017–2026 · strength 2.27
  3. Shunsuke Onoe · 7 shared papers, 2020–2025 · strength 1.27
  4. Masaki Sunagawa · 7 shared papers, 2017–2025 · strength 1.26
  5. Toshio Kokuryo · 8 shared papers, 2015–2025 · strength 1.18
  6. Hiroki Kawashima · 6 shared papers, 2018–2026 · strength 0.97
  7. Osamu Maeda · 6 shared papers, 2018–2026 · strength 0.97
  8. Yasuhiro Kodera · 7 shared papers, 2018–2025 · strength 0.94
  9. Masamichi Hayashi · 6 shared papers, 2018–2026 · strength 0.91
  10. Nobuhiko Nakagawa · 4 shared papers, 2025–2026 · strength 0.87
  11. Tsutomu Fujii · 6 shared papers, 2018–2026 · strength 0.80
  12. Takuya Ishikawa · 4 shared papers, 2019–2026 · strength 0.69
  13. Mitsuro Kanda · 3 shared papers, 2026 · strength 0.67
  14. Suguru Yamada · 5 shared papers, 2018–2026 · strength 0.67
  15. Tomohisa Otsu · 3 shared papers, 2025–2026 · strength 0.65
  16. Shoji Kawakatsu · 2 shared papers, 2025 · strength 0.47
  17. Shinji Mii · 2 shared papers, 2026 · strength 0.45
  18. Ryo Ashida · 2 shared papers, 2026 · strength 0.45
  19. Nobumasa Mizuno · 2 shared papers, 2026 · strength 0.45
  20. Motokazu Sugimoto · 2 shared papers, 2026 · strength 0.45
  21. Katsuhiko Uesaka · 2 shared papers, 2026 · strength 0.45
  22. Hirochika Toyama · 2 shared papers, 2026 · strength 0.45
  23. Atsuyuki Maeda · 2 shared papers, 2026 · strength 0.45
  24. Keizo Fujita · 2 shared papers, 2026 · strength 0.45
  25. Haruyoshi Tanaka · 2 shared papers, 2025–2026 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.